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Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon histologic
variant, and the optimal treatment of stage I-II NLPHL is undefined. We conducted a
multicenter retrospective study including patients ‡16 years of age with stage I-II NLPHL
diagnosed from 1995 through 2018 who underwent all forms of management, including
radiotherapy (RT), combined modality therapy (CMT; RT1chemotherapy [CT]), CT, ob-
servation after excision, rituximab and RT, and single-agent rituximab. End points were
progression-free survival (PFS), freedom from transformation, and overall survival (OS)
without statistical comparison between management groups. We identified 559 patients
with median age of 39 years: 72.3% were men, and 54.9% had stage I disease. Median
follow-up was 5.5 years (interquartile range, 3.1-10.1). Five-year PFS and OS in the entire
cohort were 87.1% and 98.3%, respectively. Primary management was RT alone (n 5 257;
46.0%), CMT (n 5 184; 32.9%), CT alone (n 5 47; 8.4%), observation (n 5 37; 6.6%),
rituximab and RT (n 5 19; 3.4%), and rituximab alone (n 5 15; 2.7%). The 5-year PFS rates were 91.1% after RT,
90.5% after CMT, 77.8% after CT, 73.5% after observation, 80.8% after rituximab and RT, and 38.5% after rituximab
alone. In the RT cohort, but not the CMT cohort, variant immunoarchitectural pattern and number of sites >2 were
associatedwith worse PFS (P < .05). Overall, 21 patients (3.8%) developed large-cell transformation, with a significantly
higher transformation rate in thosewith variant immunoarchitectural pattern (P5 .049) and number of involved sites >2
(P 5 .0006). OS for patients with stage I-II NLPHL was excellent after all treatments. (Blood. 2020;135(26):2365-2374)
Introduction
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an
uncommon subtype of Hodgkin lymphoma representing ;5% of
cases.1NLPHLmost frequently presents as early-stagedisease,without
B symptoms, and with male predominance.1,2 In contrast to classic
Hodgkin lymphoma, the malignant cells of NLPHL express the CD20
marker and typically lack the expression of CD15 and CD30.3 An early
clinical-pathologic study demonstrated that NLPHL is characterized by
an indolent clinical course with excellent overall survival (OS) but with
frequent relapses occurring even decades after initial diagnosis.4
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Most clinical evidence that guides management of early-stage
NLPHL arises from studies that used radiation alone or
combined-modality therapy (CMT), as patients were often treated
according to classic Hodgkin lymphoma protocols.5-9 Given the
excellent prognosis, many groups have investigated de-
escalation of treatment. As one example, in a large retrospec-
tive series from the German Hodgkin Study Group (GHSG),
patients with stage IA NLPHL who received limited radiation
alone had a progression-free survival (PFS) rate equivalent to that
of patients treated with CMT, leading to the adoption of
involved-field radiation therapy (IFRT) as the standard for stage
IA NLPHL.10,11 Further, reports from pediatric cohorts showed
reasonable outcomes after surgical excision alone for localized
disease.12,13 In addition, given the excellent OS, it has been
proposed that surveillance after initial diagnosis would be a
reasonable strategy for adult populations, reserving treatment
for those who progress.14 Despite the CD201 molecular marker,
rituximab alone has not been associated with durable
responses.11,15 These largely single-institution studies highlight
the challenge of defining the optimal treatment of stage I-II
NLPHL.
Given the low incidence of NLPHL, the conduct of prospective
clinical trials is challenging. Thus, we sought to perform a large,
multicenter, retrospective study of patients with stage I-II NLPHL
treated with any modality from 1995 through 2018.
Materials and methods
Patients
We conducted a multi-institutional, retrospective analysis in-
cluding data from 18 institutions. Each center obtained in-
stitutional review board approval or the equivalent and sent
anonymous patient data to a single database. Details of patient
characteristics, treatment, follow-up, and outcomes were uni-
formly collected according to a prospective survey protocol.
Inclusion criteria included age $16 years, diagnosis of stage I-II
and CD201 disease, managed by observation, systemic therapy,
and/or RT at the participating institution from 1995 through
2018. Patients were classified according to GHSG favorable
vs unfavorable criteria.16 Patients with concurrent diagnosis of
diffuse large B-cell lymphoma were excluded.
Recorded data included patient age, sex, Eastern Cooperative
Oncology Group (ECOG) performance status, immunohisto-
chemistry, immunoarchitectural pattern (IAP) when available,17
serum laboratory values, erythrocyte sedimentation rate (ESR),
stage, number of anatomic sites, bone marrow biopsy status,
presence of B symptoms, baseline imaging, management type
and dates, and treatment toxicity. Biopsy and resection extent
were recorded. RT technique (extended field, IFRT, involved site
[ISRT], and involved node [INRT]18), beam type (photon, elec-
tron, or proton), dose, and fractionation were recorded. Che-
motherapy (CT) regimen and number of cycles were recorded.
Management, follow-up, and outcomes
Management was according to treating physician and patient
preferences. Few patients were treated according to prospective
protocols, with the exception of some who were enrolled on a
trial utilizing rituximab alone.15
Routine follow-up visits and laboratory testing details and fre-
quency were conducted according to physician and institutional
practices and were not recorded in this study. Imaging response
to treatment, when available, was collected. Metabolic response
was assessed with 18F-FDG positron emission tomography-
computed tomography (PET-CT) and, when available, scored
according to the Deauville 5-point scale.19 Size response was
assessed according to the following criteria: complete response
(CR), no residual abnormality; partial response, reduction in
diameter by at least 30%; stable disease, no change in lesion
diameter; and progressive disease, a 20% increase in diameter
or new lesions.20,21 In patients without response imaging, clinical
evaluation was used to assess response.
We recorded each patient’s last known vital status. In those who
experienced relapse, we collected restaging information, in-
cluding method of relapse detection (patient symptoms, clinical
examination, or surveillance imaging), histology of relapse,
stage, location of relapse in reference to the initial site of dis-
ease, salvage treatments, and response to salvage treatments.
Treatment-related toxicities
Treatment-related acute and late toxicities were scored
according to The Common Terminology Criteria for Adverse
Events (CTCAE, version 5). Second cancers, hypothyroidism,
cardiac disease, and any other late toxicities were recorded in
reference to RT volumes or if secondary to systemic therapy.
End points
PFS after primary and salvage treatment, OS and freedom from
transformation to large-cell lymphoma were assessed. PFS was
measured from the date of diagnosis to the date of recurrent/
progressive lymphoma (including large-cell transformation) or
death from any cause. OS was measured from date of diagnosis
to date of death. Freedom from transformation was measured
from date of diagnosis until biopsy-proven diagnosis of large-
cell lymphoma.
Statistical analyses
PFS, OS, and freedom from transformation were measured
by the Kaplan-Meier method. There was not a significant
competing risk of death in measurements of freedom from
transformation. Follow-up was measured by using the reverse
Kaplan-Meier approach. Patient andgroupbaseline characteristics
were compared by using Fisher’s exact test (small count data),
x2 test (multigroup count data), Mann-Whitney U test (continuous
data), and analysis of variance (multigroup continuous data).
In 260 cases, ESR was missing and was imputed by using linear
regression from hemoglobin if available or from the sample
mean.22 When classifying patients as favorable by GHSG criteria,
we excluded patients who had mediastinal involvement without
size or indication of bulk of disease. Because of the potential for
selection bias and the retrospective nature of the study, out-
comes of patients after use of different management strategies
were not compared. Cox regression was performed with the
following R packages: survival and competing-risks regression
for stratified and clustered data. To adjust for treatment center,
we performed a stratified Cox regression analysis, with clustering
by institution. For the univariable and multivariable (MVA)
analyses, the following variables had missing data that were
imputed using the average for continuous variables or the mode
for binary variables: size (n 5 113; 20.2%), bone marrow biopsy
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status (n 5 15; 2.7%), and infradiaphragmatic involvement
(n 5 4; 0.7%). For the subgroup analyses involving IAP, no
imputation was performed, with the number included in the
analysis listed. All other variables included in regression analyses
did not have missing values. Variables with P , .05 on uni-
variable regression analysis were included in MVA. We ensured
that the proportional hazards assumption was met by de-
termining the relationship of parameter residuals and survival
time, as well as with visualization of log(2log[survival]) plots. All
analyses were performed with R (version 3.6; Vienna, Austria).
Results
Patients
There were 559 eligible patients treated at 18 participating
institutions from 1995 through 2018. Pathologically diagnosed
cases were identified from databases independent of managing
medical specialty in 9 institutions (50%), databases of cases
managed by both radiation and medical oncology in 3 (16.7%),
and databases of cases managed by radiation oncology for
5 (27.8%) or medical oncology alone for 1 (5.6%; supplemental
Table 1, available on the Blood Web site).
Baseline patient characteristics are shown in Table 1. Median
follow-up of the entire cohort was 5.5 years (interquartile range
[IQR], 3.1-10.1) and was significantly shorter in patients un-
dergoing observation (Table 1; P 5 .02; excluding observation
subgroup, P5 .78); 134 patients (24.0%) had at least 10 years of
follow-up. Patients had a median age of 39 years (range, 16-90
years), male preponderance (72.3%), and good ECOG perfor-
mance status (0-1, 86.9%). Just over half had stage I NLPHL
(54.9%). Few had B symptoms (6.8%) or extranodal involvement
(5.7%). The majority of patients underwent staging with PET-CT
(71.2%) and bone marrow biopsy (55.6%). Approximately one-
third had the IAP described.
Baseline patient and treatment details by
management type
Primary management included RT alone in 257 patients (46.0%),
CMT in 184 (32.9%), CT alone in 47 (8.4%), observation after
biopsy/resection in 37 (6.6%), rituximab and RT in 19 (3.4%), and
rituximab alone in 15 (2.7%). As shown in Table 1, there were
differences in baseline factors between the different manage-
ment groups including age (P 5 .01), ECOG performance score
(P5 .002), stage (P, .0001), and the percentage of patients with
variant IAP (P 5 .01).
We classified patients according to the GHSG clinical criteria,
with the majority being favorable (84.6%, Table 1). There was no
difference in the percentage of patients who were favorable by
GHSG criteria when considering only those without imputed ESR
values (P 5 .61). There was a significant difference in the per-
centage of patients who were favorable by GHSG criteria
according to management strategy (P , .0001). Nine (1.6%)
patients were not classifiable by GHSG criteria, as they had
mediastinal involvement without size measurement or docu-
mentation of disease bulk.
Focusing on details of patients who underwent treatment,
RT techniques used in the RT-alone group included IFRT in
163 patients (63.4%), INRT/ISRT in 66 (25.7%), and EFRT in
28 (10.9%). The median RT dose was 36 Gy (IQR, 30.6-36) in the
RT alone group and 30.6 Gy (IQR, 30-35) in the CMT/rituximab
and RT groups (supplemental Table 2). The most common CT
regimens used in patients receiving CMT were doxorubicin
(Adriamycin), bleomycin, vinblastine, and dacarbazine in 149
(ABVD, 81.0%; median, 3 cycles; IQR, 2-4) plus rituximab in a
subset (n 5 23; 15.4%) followed by cyclophosphamide, doxo-
rubicin, vincristine, and prednisone with rituximab in 24 (R-CHOP
13.0%; median, 4 cycles; IQR, 3-4). The most common CT
regimens used in patients receiving CT alone were ABVD in
32 (68.1%; median 4 cycles; IQR, 4-6) plus rituximab in 6 (18.8%),
followed by R-CHOP in 10 (21.3% all with stage II NLPHL;
median 6 cycles; IQR, 6-6]). In those receiving CT with ABVD,
11 (23.4%) received 6 cycles and 1 (2.1%) received 8 cycles, of
whom all except 1 had stage II NLPHL. Additional CT regimens
used are summarized in supplemental Table 3. Four patients
were scheduled to receive RT after CT but did not, for the
following reasons: 1, patient preference (after 4 cycles of ABVD
with a CMR); 1, lack of insurance approval (after 3 cycles of ABVD
with a CMR); and 2, bleomycin lung toxicity (grade 4 and 5 lung
toxicities after 3 and 2 cycles of ABVD, respectively). Nineteen
patients (3.4%) received rituximab and RT without CT. All pa-
tients selected for rituximab and RT received 4 doses of ritux-
imab with the exception of 1 who received 6 doses and another
who received 8. Patients who were selected for rituximab alone
received a median of 4 doses (IQR, 4-5).
Thirty-two (86.5%) of the patients who were observed after di-
agnosis underwent excisional biopsies, and 25 (67.6%) had
complete resection without known residual remaining lym-
phoma. Thirty-two (86.5%) had stage I NLPHL. Thirty-one pa-
tients (83.8%) had a staging PET-CT, performed either before or
shortly after surgery.
Outcomes and response to management
The 5-year PFS and OS in the entire cohort were 87.1% (95% CI,
83.6%-90.0%) and 98.3% (95% CI, 96.4%-99.2%), respectively
(Figure 1). The 5-year PFS rates by management strategy were
91.1% (95% CI, 85.3%-94.7%) with RT, 90.5% (95% CI, 84.8%-
94.1%) with CMT, 77.8% (95% CI, 61.3%-88.0%) with CT, 73.5%
(95% CI, 50.6%-87.0%) with observation, 80.8% (95% CI, 41.0%-
95.1%) with rituximab and RT, and 38.5% (95% CI, 14.0%-62.8%)
with rituximab alone (supplemental Figure 1A). The 5-year PFS
in patients observed after having a complete resection was
79.1% (95%CI, 52.3%-91.9%). The 5-yearOS rates bymanagement
strategy were 99.4% (95%CI, 96.1%-99.9%) with RT, 99.4% (95%
CI, 95.9%-99.9%) with CMT, 97.9% (95% CI, 85.9%- 99.7%) with
CT, 89.8% (95% CI, 64.3%-97.4%) with observation, 100%
with rituximab and RT, and 92.3% (95% CI, 56.6%-98.8%)
with rituximab alone (supplemental Figure 1B).
The RT and CMT cohorts had sample sizes large enough to
perform subset analyses. Figure 2 demonstrates the PFS rates of
stage I and II NLPHL in the RT and CMT cohorts. In addition,
there was no significant difference in the 5-year PFS of patients
classified as favorable vs unfavorable by the GHSG criteria for
those receiving RT (91.3% for favorable vs 88.9% for unfavorable;
P 5 .31) or CMT (91.1% for favorable vs 91.3% for unfavorable;
P 5 .35).
Univariable and multivariable regression analyses of PFS were
performed separately in the RT and CMT cohorts, as they were
sufficiently large enough for regression analyses. Focusing on
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the RT cohort, on univariable analysis, number of involved sites
.2 and variant IAP were significantly associated with worse PFS,
whereas infradiaphragmatic involvement was associated with
improved PFS (P , .05; Table 2). Figure 3A demonstrates the
PFS rates in patients with 1 to 2 sites vs .2 sites receiving RT
(P 5 .02). On MVA, only .2 involved sites and variant IAP
remained significantly associated with worse PFS (P , .05;
Table 2; Figure 3C). There was no significant association be-
tween RT dose (P5 .19) or INRT/ISRT volumes (P5 .39) and PFS.
There was no significant association between variant IAP and OS
in those receiving RT (P 5 .91).
Looking at the CMT cohort, increasing age, the presence of B
symptoms, and stage II were significantly associated with worse
PFS (P, .05, Table 2). Figure 3B demonstrates that there was no
significant difference in PFS rates in patients with 1 to 2 vs .2
sites of involvement who received CMT (Figure 3B; P5 .81). On
MVA, only the presence of B symptoms remained significantly
associated with worse PFS in the CMT cohort (P5 .047; Table 2;
Figure 3D).
OS was excellent regardless of management strategy (supple-
mental Figure 1B). There were 24 reported deaths with 7 con-
firmed lymphoma-specific deaths. Nonlymphoma-specific
deaths included 2 cardiac events (1 received 6 cycles of ABVD
and mediastinal IFRT along with BEACOPP baseline [doxoru-
bicin [Adriamycin], bleomycin, vincristine (Oncovin), cyclo-
phosphamide, procarbazine, etoposide and prednisone] for
relapsed NLPHL and the other received mediastinal IFRT alone),
1 from bleomycin lung toxicity, 1 gastrointestinal bleed, 1
secondary to thrombocytopenia possibly due to ITP, 1 from
acute myeloid leukemia, 1 from pancreatic cancer, 1 from
pneumonia, and 5 noncancer deaths not otherwise specified.
Four deaths were of unknown cause.
Response to management by imaging modality
A subset of patients had postmanagement PET-CT (n 5 227;
40.6%) or CT (n 5 332; 59.4%) performed to assess response
within 6months (supplemental Figure 2). On univariable analysis,
failure to achieve a complete metabolic response (no CMR) was
associated with an 8 times higher risk of progression (hazard ratio
[HR], 8.26; 95% CI, 3.2-21.3; P 5 1.3e-5), which was a larger
effect size than failure to achieve a complete response (no CR) by
CT criteria (HR, 2.89; 95% CI, 1.7-4.93; P 5 9e-5).
Recurrence and salvage treatment
Progressive lymphoma developed in 86 patients (15.4%) at a
median of 4.4 years (IQR, 1.7-6.9). Progression events included 9
refractory cases (3 treated with RT, 2 with CMT, and 4 with CT) in
which an initial CMR/CR or clinical response to primary treatment
was not achieved. The remainder of progression events were
relapses that occurred after an initial CMR/CR or clinical re-
sponse. Median follow-up after progression was 5.8 years (IQR,
3.0-8.4). Seventy patients (81.4%) underwent biopsy at pro-
gression and 20 patients had relapse stage III-IV NLPHL at
progression. In the majority of patients, progressive lymphoma
was detected by surveillance PET-CT or CT (n5 55; 64.0%), with
smaller subsets identified by patient symptoms (n 5 18; 20.9%),
by unknownmethods (n5 9; 10.5%), and by clinical examination
(n 5 4; 4.7%). There was a significantly higher rate of local-only
progression (within the initially involved anatomic region) in
patients who did not receive RT as part of primary management
vs those who received RT (21.6% vs 3.0%, respectively;
P , .0001; Figure 4A). Patients who underwent observation had
a nonsignificantly higher rate of relapse stage III and IV NLPHL
(n5 3 of 4; 75%) vs all others (n5 17 of 59; 28.8%; P5 .09). Five
(5.8%) patients did not have restaging information available.
After progressive NLPHL, 7 (10.8%) patients underwent obser-
vation, 16 (24.6%) received RT alone or CMT for stage I and II
recurrence, 29 (44.6%) received CT (n 5 11 with rituximab),
11 (16.9%) received rituximab alone, and 2 (3.1%) underwent
autologous stem cell transplant. Five-year PFS after salvage
treatment was 85.1% (95%CI, 72.1%-92.4%) and did not differ in
patients who underwent initial observation (P 5 .71). The 5-year
OS in those without biopsy-proven transformation was
93.1% (95% CI, 82.6%-97.4%; Figure 4B). We did not observe
worse OS in those that relapsed within 1 (P 5 .37) or 2 years
(P 5 .16) of initial diagnosis.
Transformation
Twenty-one (3.8%) patients underwent transformation to diffuse
large B-cell lymphoma or T-cell–rich B-cell lymphoma at a
median of 3.6 years (IQR, 2.5-7.8) after primary management.
Four lymphoma-specific deaths occurred in patients who ex-
perienced transformation, representing more than half of
lymphoma-specific deaths. The 5-year freedom from trans-
formation was 96.7% (95% CI; 94.4%-98.1%; Figure 4C). We
performed univariable Cox regression and found a significantly
increased risk of transformation in those with number of involved
sites .2 and variant IAP (P , .05; supplemental Table 5).
Median follow-up after transformation was 6.7 years (IQR, 1.5-
8.8). With the exception of 1 patient who was lost to follow-up
and another who died of progressive lymphoma 3 weeks after
diagnosis of transformation, all patients underwent salvage
treatment. The 5-year PFS and OS were 62.2% (95% CI, 36.1%-
80.1%) and 88.4% (95% CI, 60.2%-97.0%; Figure 4B), re-
spectively, after diagnosis of transformation. The most common
salvage treatment was R-CHOP (n5 15; 71.4%; median 6 cycles;
IQR, 3-6) plus RT in a subset (n 5 5). Two others received
rituximab-based CT (n 5 1; R-ABVD, and n 5 1 dose-adjusted
rituximab, etoposide, prednisone, vincristine, cyclophospha-
mide, doxorubicin). Two patients underwent autologous stem
cell transplantation.
Toxicities
Information regarding treatment-associated toxicities was
available for 421 (75.3%) patients. Acute grade 1 to 3 toxicities
occurred in 76 (37.6%) patients who received RT alone,
51 (39.2%) after CMT, 27 (59.3%) after CT, 5 after rituximab and
RT (26.3%), and 2 after rituximab alone, and all resolved, with the
exception of alopecia in a patient who received RT. Grade 4
toxicities were rare but occurred in patients receiving RT (n 5 1
laryngeal edema), CMT (n5 1 neutropenia), and CT alone (n5 1
bleomycin lung toxicity and n 5 1 thrombocytopenia). One
grade 5 toxicity related to bleomycin lung toxicity occurred in a
patient who received CT alone.
Late toxicity was uncommon but occurred in patients who re-
ceived RT (hypothyroidism [n 5 8], cardiac disease with medi-
astinal irradiation [n 5 2], and xerostomia [n 5 1]), CMT (lung
fibrosis [n 5 2], hypogammaglobulinemia [n 5 1], cardiac dis-
ease without mediastinal irradiation [n 5 1], and neuropathy
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[n 5 2]), and CT alone (cardiac disease after anthracycline
therapy [n 5 3] and pulmonary fibrosis [n 5 2]).
Second cancers
Second cancers occurred in 24 (4.3%) patients during follow-up
(supplemental Table 6). Four (0.9%) patients who received RT
(with or without systemic therapy) developed cancers within the
RT treatment volume.
Discussion
In this study, we observed that patients with early-stage NLPHL
who received definitive RT-containing therapy had a PFS of
greater than 90% at 5 years, and greater than 70% at 10 years.
One quarter of the patients in our series had greater than
10 years of follow-up, and there was an ongoing risk of relapse
for at least 15 years after diagnosis. After treatment with RT
alone, we identified that both the involved sites .2 and variant
IAP were associated with worse PFS and may warrant treatment
intensification via CMT. Only the presence of B symptoms
was a poor prognostic factor for PFS in the CMT cohort after
MVA. However, similar to recent reports from the GHSG, non-
lymphoma causes of death were greater than lymphoma-specific
deaths in our study, and longer follow-up is necessary to further
define the second malignancy risk in adult populations.23 Im-
portantly, OS was excellent after all types of initial management.
Several previous studies have reported excellent outcomes after
RT alone for early-stage NLPHL. The GHSG reported a favorable
prognosis for patients with stage IA NLPHL who received RT,
with no benefit seen from the addition of CT.5,11 The treatment of
stage IIA NLPHL without risk factors is currently controversial: the
European Society of Medical Oncology recommends CMT,
whereas the National Comprehensive Cancer Network (NCCN)
recommends RT alone for many patients.24,25 In patients with
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Figure 2. PFS of the RT and CMT cohorts by stage. Kaplan-Meier curves demonstrate the PFS of patients with stages I and II NLPHL receiving RT (A) or CMT (B). Five-year PFS
for patients receiving RT was 89.8% (95% CI, 82.8%-94.0%) for stage I and 93.9% (95% CI, 84.4%-97.7%) for stage II. Five-year PFS for patients receiving CMT was 95.3% (95% CI,
















































Figure 1. Outcomes for the entire cohort. Kaplan-Meier curves demonstrate PFS (A) and OS (B) of patients with stage I-II NLPHL.
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Table 2. Univariate and analysis and MVA for PFS using stratified Cox regression adjusted for treatment center
RT PFS (38 events)
Combined modality
therapy PFS (31 events)
Variable Univariate MVA1 MVA2* Univariate MVA
Age (continuous)
HR 1.01 — — 1.02 1.02
95% CI 0.99-1.04 1.01-1.04 0.99-1.04
P .24 .009 .08
Male sex
HR 1.17 — — 2.07 —
95% CI 0.59-2.35 0.90-4.78
P .65 .09
B symptoms
HR — — — 2.39 1.91
95% CI 1.25-4.56 1.01-3.63
P .008 .047
Bone marrow biopsy
HR 0.70 — — 1.02 —
95% CI 0.41-1.20 0.50-2.11
P .20 .95
Extranodal disease
HR 1.58 — — 1.00 —
95% CI 0.53-4.67 0.22-4.61
P .41 1.00
Stage II
HR 1.35 — — 2.26 2.04
95% CI 0.68-2.69 1.01-5.07 0.85-4.90
P .40 .048 .11
Noncontiguous stage II
HR 0.76 — — 0.76 —
95% CI 0.18-3.13 0.23-2.55
P .70 .66
Pretreatment size (continuous), cm
HR 1.06 — — 1.03 —
95% CI 0.98-1.13 0.95-1.11
P .47 .47
PET staged
HR 0.98 — — 1.00 —
95% CI 0.40-2.44 0.47-2.12
P .97 1.00
Number of involved sites >2
HR 2.51 2.66 2.66 1.19 —
95% CI 1.17-5.40 1.33-5.32 1.23-5.75 0.26-5.40
P .02 .006 .01 .43
Infradiaphragmatic
HR 0.22 0.22 0.24 0.56 —
95% CI 0.06-0.79 0.07-0.70 0.04-1.46 0.20-1.60
P .02 .01 .12 .28
Variant IAP†
HR 2.46 — 2.70 0.51 —
95% CI 1.06-5.66 1.14-6.40 0.05-5.22
P .04 .02 .57
—, regression did not converge.
*MVA2 performed using the subset with IAP available.
†Subset with IAP available: RT cohort (n 5 100; 22 events); CMT cohort (n 5 76; 12 events).
STAGE I-II NODULAR LYMPHOCYTE-PREDOMINANT HL blood® 25 JUNE 2020 | VOLUME 135, NUMBER 26 2371
those with stage I.9,26 Wirth et al26 reported a large multicenter
study of patients receiving RT alone from 1969 through 1995,
with freedom from progression of 84% and 73% in patients with
stages I and II NLPHL, respectively. Patients with stage II and
only 2 sites of disease had a an outcome similar to that of
patients with stage I disease. We also found that patients who
received RT with .2 sites had a worse PFS. Conversely, there
was no difference in PFS in patients who received CMT with .2
sites vs all others, suggesting that treatment intensification may
improve outcomes of the subset with .2 sites of involvement.
Radiotherapy
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Figure 3. PFS analyses for the RT and CMT cohorts. (A-B) PFS in patients with 1 to 2 sites vs.2 sites of involvement receiving RT (P5 .02) and CMT (P5 .81). (C-D) For patients












































































Figure 4. Patterns of failure, transformation rate, and survival after progression. (A) The patterns of failure for patients selected for RT/CMT or other primary man-
agements. (B) OS for patients who progress after primary management, stratified by transformation status. (C) Freedom from transformation to large-cell lymphoma.
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Notably, it appears that there is no decrease in local disease
control with smaller, more contemporary RT volumes similar to
findings by Pinnix et al.27 We also did not observe worse PFS in
patients with infradiaphragmatic involvement, similar to reports
by other groups.28 The small subset of patients in our cohort with
stage I NLPHL who received CT had a 5-year PFS of 90.9%,
similar to reports by other groups, suggesting CT alone may also
achieve excellent disease response.6,29
Recently, there has been interest in further de-escalation of
upfront treatment of NLPHL, given the high response to salvage
treatment at time of relapse. We found that approximately two-
thirds of patients with predominantly stage I NLPHL selected for
observation, of whom most had complete resection and PET
staging, were also free of progressive lymphoma or death at
5 years postresection. A prior prospective pediatric study by
Appel et al12 showed a 5-year event-free survival rate of 77.1%
after total resection, which is remarkably similar to our 5-year PFS
of 79.1% in those reported as having a complete resection.
Borchmann et al14 recently reported a large single-institution
cohort with a 5-year PFS of 65% for early-stage NLPHL. An older
French registry study showed a 5-year PFS of 59% in adult
patients although they did not specify the proportion with
completely resected disease.30 Both Borchmann et al14 and
Appel et al12 reported that progressions after active surveillance
were most commonly of limited stage (60% and 100%, re-
spectively). In our cohort of patients who were initially observed,
3 of 4 NLPHL relapses with restaging information were of ad-
vanced stage. Thus, for adult patients selected for observation,
salvage treatment with RT alone may not always be an option.
Previously, the GHSG showed worse PFS for variant IAP vs
typical pattern among patients with stage I-IV disease and re-
cently showed a shorter median time to recurrence in those with
variant IAP vs typical pattern after treatment with rituximab alone
for stage IA NLPHL.31,32 We similarly found worse PFS in patients
with variant IAP in early-stage NLPHL after treatment with RT
alone. We did not observe any association between variant IAP
and PFS in those receiving CMT, suggesting that the addition of
CT may improve outcomes for this subset. Interestingly, we
found a nearly 3 times higher risk of transformation in patients
with variant IAP (HR, 2.72), further confirming that patients in this
subset are at risk of progression to aggressive lymphoma.
Given the excellent survival of patients with early-stage NLPHL,
any risk of late effects with a given treatment must be consid-
ered. We observed very low rates of late toxicity in patients who
received definitive RT or CMT (3.9%). Although we observed
very low rates of second cancer (,5% overall, with ,1% oc-
curring within RT volumes), our median follow-up was not ad-
equate to capture the late risk of second cancers associated with
RT and CT. The GHSG reported long-term outcomes for NLPHL
after treatment with RT/CMT/CT, with 10.2% of patients de-
veloping a second malignancy within a median observation time
of 9.2 years.23
Limitations of our study include its retrospective nature; lack
of central pathology and imaging review (including lack of
Deauville scoring by nuclear medicine specialists); and most
important, relatively small subsets of patients selected for
non-RT–containing management approaches, with an uneven
distribution of prognostic factors between groups limiting any
statistical comparisons between management groups. Ulti-
mately, controlled clinical trials are necessary to determine
the optimal treatment of early-stage NLPHL, but will be
challenging to conduct given the disease incidence and
excellent OS.
In conclusion, our data provide further evidence of the efficacy of
RT alone for stage I NLPHL. RT alonemay also be appropriate for
selected patients with stage II disease without risk factors. CMT
warrants consideration for patients with unfavorable features,
such as variant IAP or stage II disease with 3 or more sites of
involvement. Observation appears to be an acceptable alter-
native for patients with stage I NLPHL who are entirely without
evidence of disease after excision, particularly in settings where
RT poses a late toxicity risk.
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